

IDMA BULLETIN

VOL. NO. 53

ISSUE NO. 38 (PAGES: 24)

08 TO 14 OCTOBER 2022

ISSN 0970-6054

WEEKLY PUBLICATION



INDIAN PHARMA - GLOBAL HEALTH CARE

INDIAN DRUG MANUFACTURERS' ASSOCIATION

IDMA Symposium on Nasal and Pulmonary Drug Delivery

on November 10 & 11, 2022

at Hotel Sofitel, BKC, Mumbai

(Details on Page: 8)



HIGHLIGHTS

- ★ **DPIIT invites suggestions to enhance Ease of Doing Business and Ease of Living** *(Page No. 13)*
- ★ **IPC launches 1000th IP Reference Standard**
(Page No. 15)
- ★ **Codeine cough syrup rules may get tighter**
(Page No. 16)

IN-DEPTH.
AND WIDE KNOWHOW.
THAT'S OUR BRAND OF
EXPERTISE.



Dear Partner,

Signet is driven by expertise, be that technical or commercial. Nowhere is that more evident than in our partnership with highly reputed companies Dead Sea Periclase, Dead Sea Works Ltd. and Scora, our source of ICL Industrial Products.

Dead Sea Periclase, with its signature 'Aman' process, provides us with the highest quality magnesium oxide, hydroxide and carbonate products. Dead Sea Works Ltd., from whom we source exceptional potassium chloride, is also recognised as the world's top provider. While for all things calcium and magnesium, the specialists at Scora fulfil our every need. So that we can do the same for you.

By associating with expertise, we enhance our own. Making us the foremost name in pharmaceutical excipients.

Signet-ure
expertise



MAGNESIUM OXIDE
MAGNESIUM HYDROXIDE
MAGNESIUM CARBONATE
POTASSIUM CHLORIDE, REFINED
CALCIUM CARBONATE (SCORALITE)
CALCIUM CARBONATE DC (SCORALITE DC)

Signet

The Complete Excipients Company



Founder Editor:
Dr. A. Patani

Editor:
Dr. Gopakumar G. Nair

Associate Editors:
Mr. J. L. Sipahimalani
Dr. Nagaraj Rao
Dr. George Patani

National President
Dr. Viranchi Shah

Immediate Past National President
Mr. Mahesh Doshi

Senior Vice-President
Mr. Bharat N Shah

Vice-Presidents:
Dr. George Patani
(Western Region)

Mr. Asheesh Roy
(Eastern Region)

Mr. B K Gupta
(Northern Region)

Mr. T Ravichandiran
(Southern Region)

Hon General Secretary
Mr. Mehul Shah

Hon Joint Secretaries
Mr. Kamlesh C Patel
Mr. Pranav Choksi

Hon Treasurer
Mr. Vinay Pinto

For information contact :
IDMA Secretariat: (H.O.)

Daara B Patel
Secretary-General

Melvin Rodrigues
Sr Manager (Commercial & Administration)

IDMA State Boards	Chairman
▶ Gujarat State Board	: Dr. Shrenik K Shah
▶ Haryana State Board	: P K Gupta
▶ Himachal Pradesh & Uttarakhand State Board	: R C Juneja
▶ Karnataka State Board	: S M Mudda
▶ Madhya Pradesh State Board	: Paresh Chawla
▶ Tamil Nadu, Puducherry & Kerala State Board	: J Jayaseelan
▶ Telangana State Board	: Shaik Janimiya
▶ West Bengal State Board	: Shiv Sagar Tewari
IDMA Delhi Office	: Ashok Kumar Madan Executive Director S. Ranganathan Asst. Manager (Administration)

A Publication of
Indian Drug Manufacturers' Association
102-B, 'A-Wing', Poonam Chambers,
Dr. A.B. Road, Worli, Mumbai - 400 018
Tel : 022-2494 4624 / 2497 4308 Fax: 022-2495 0723
e-mail: publications@idmaindia.com/
actadm@idmaindia.com/ website: www.idma-assn.org

Published on 7th, 14th, 21st and 30th of every month

Annual Subscription
₹ 1000/- (for IDMA members)
₹ 2000/- (for Government Research/Educational Institutions)
₹ 4000/- (for non-members) US\$ 400 (Overseas)
Please send your payment in favour of
Indian Drug Manufacturers' Association

OPINIONS EXPRESSED BY THE AUTHORS OF INDIVIDUAL ARTICLES
DO NOT NECESSARILY REPRESENT THE OFFICIAL VIEW OF IDMA.

IDMA BULLETIN

Vol. No. 53

Issue No. 38

08 to 14 October 2022

IDMA ACTIVITIES:

IDMA - GSB jointly with BCIL and SNL, USA Organizing Two day training programme on "Know-Your-Customer (KYC) best practices" for Indian Pharmaceutical industry at Hotel Courtyard by Marriott, Ahmedabad on November 14-15, 20224

Registrations open for ET MSME Awards 2022. Apply Now!.....6

REGISTER NOW: IDMA Symposium on Nasal and Pulmonary Drug Delivery on November 10 & 11, 2022 at Hotel Sofitel, BKC, Mumbai8

DGFT MATTERS:

Amendment in Standard Input Output Norms (SION) of 'Chemical & Allied Product' (Product Code 'A') - reg.....11

PRESS RELEASE:

Direct Tax Collections for F.Y. 2022-23 up to 08.10.2022.....12

DPIIT MATTERS:

DPIIT invites suggestions to enhance Ease of Doing Business and Ease of Living13

NATIONAL NEWS:

Cruising Towards TB Elimination15

IPC launches 1000th IP Reference Standard.....15

Codeine cough syrup rules may get tighter16

Govt planning 7-8 more PLI schemes to expand coverage.....17

Pharma Exporters clock big gains18

Biocon Foundation Receives 'Mahatma Award 2022 for Excellence in Social Good'18

.....
IDMA Bulletin Subscription Form..... 14

60TH IDMA Annual Publication 2022 19

IDMA Publications Rate Card.....20

IDMA Bulletin Tariff Card22

Advertisements..... 2, 23 & 24

IDMA – GSB jointly with BCIL and SNL, USA Organizing Two day training programme on “Know-Your-Customer (KYC) best practices” for Indian Pharmaceutical industry at Hotel Courtyard by Marriott, Ahmedabad on November 14-15, 2022

Dear Member,

Greetings of the day!!!!

We are pleased to inform you that Indian Drug Manufacturers' Association – Gujarat State Board (IDMA – GSB), jointly with Biotech Consortium India Limited (BCIL), New Delhi and Sandia National Laboratories (SNL), USA is organizing a 02 -day training programme on “**Know-Your-Customer (KYC) best practices**” for Indian Pharmaceutical industry at **Hotel Courtyard by Marriott, Ramdev Nagar Cross Road, Satellite Road, Ahmedabad on November 14-15, 2022.**

The objective of the training programme is to raise awareness of chemical weapons proliferation potential and to provide Know-your-customer best practices in the pharmaceutical industry. Details are in attached pamphlet. This training is appropriate for all pharmaceutical companies producing and using potentially lethal (e.g., fentanyl) and other incapacitating and/or dissociative agents (e.g., benzodiazepines). It is designed for **pharma industry managers, security officers, regulators, and transportation logistics company managers.** There are a total 20 slots and participants will be selected based on the activities undertaken by their organization in reference to the topic of the programme and the usefulness to the participant's organization thereby achieving the objective of the training.

Kindly note that expenses towards travel by Air (economy) / Train (2nd AC fare) / Taxi and boarding & lodging (accommodation at Hotel Courtyard by

Marriott and meals) of participants will be borne by SNL/BCIL. More details and registration link are given in the attached pamphlet.

We request you to nominate concerned officials from your organization for the training programme and request them to register positively by **October 15, 2022.**

There is No registration fee, however, the REGISTRATION IS MANDATORY for consideration in the training programme.

With kind regards,

**Sumit J. Agrawal
Hon. Secretary
IDMA - GSB**

Brief about organizing partners:

a) Biotech Consortium India Limited (BCIL), New Delhi

BCIL is a company set up in 1990 as an initiative of the Department of Biotechnology (DBT), Ministry of Science & Technology, Government of India and All India Financial Institutions. As part of our activities, we are engaged in capacity building related to biosafety and chemical security issues. Such activities are undertaken in collaboration with national and international agencies.

b) Sandia National Laboratories (SNL), USA

SNL undertakes capacity building programmes, with support from US Department of State's Chemical Security Program (CSP).



Global Chemical and
Biological Security



Know-Your-Customer (KYC) Workshop for Indian Pharmaceutical Industry

14-15 November 2022, 09:00-17:00 IST

Announcement: Biotech Consortium India Limited (BCIL), Indian Drug Manufacturers' Association (IDMA) and Sandia National Laboratories (SNL) on behalf of the United States Department of State's Chemical Security Program (CSP) are organizing an in-person workshop to raise awareness of the chemical weapons (CW) proliferation potential of key pharmaceuticals and to provide Know-Your-Customer (KYC) best practices for the Indian Pharmaceutical industry. During this workshop participants will learn how to recognize suspicious purchase requests, develop customer vetting strategies, and understand regulations regarding the sale of 'dual use' chemicals that may be misused as chemical weapons. Additional topics will also include chemical security threats and chemicals of concern. The overarching focus of this event is to develop strategies that deny access to weaponizable pharmaceuticals. This workshop is appropriate for all pharmaceutical companies producing and using potentially lethal (e.g., fentanyl) and other incapacitating and/or dissociative agents (e.g., benzodiazepines).

Audience:

- Up to 20 Indian Pharma industry managers, security officers, regulators, and transportation logistics company managers.

Goal:

- Provide participants with the awareness of the chemical weapons proliferation potential of key pharmaceuticals, an understanding of KYC, and the knowledge and resources to implement KYC best practices and policies at their institutions to ensure their products are not acquired for illicit purposes.

Agenda:

14 November 2022	15 November 2022
<ul style="list-style-type: none"> • Welcome, Introduction, Goals • Industry Case Study • Chemical Security Threats • Pharmaceuticals of Concern with exercise • Illicit Procurement Tactics with Case Studies 	<ul style="list-style-type: none"> • Overview of KYC Principles and Practices • Interactive Scenario-Based Activities on KYC Indicators • KYC Implementation • Next Steps • Valedictory

Registration Site: <https://gcbs-events.sandia.gov/chemical-security-program/remote-know-your-customer-kyc-training-for-indian-pharmaceutical-industry>

Points of Contact:

Dr. Cecelia Williams, Ph.D.
Sandia National Laboratories
cwilli@sandia.gov

Dr. Andrew W. Nelson
Sandia National Laboratories
awnelso@sandia.gov

Dr. Vibha Ahuja, Ph.D.
Biotech Consortium India Limited
vibhaahuja@biotech.co.in
Phone no. 98912 44434

Registrations open for ET MSME Awards 2022. Apply Now!

Dear Member,

Greetings from The Economic Times Digital and IDMA.

IDMA is pleased to inform its members that IDMA is the Associate Partner for the ET MSME AWARDS 2022 and is herewith sharing The Economic Times Digital launch of the third edition of ET MSMEs Awards.

Over the years, organizations like: IMC Chamber of Commerce, Indian Textile Accessories & Machinery Manufacturers Association, Plastics export promotion council, Association of Diagnostic Manufactures of India, Sports Goods Foundation of India, Synthetic and Rayon textiles export promotion council and many others have associated with The Economic Times Digital.

For your reference please find the attached MSME Awards mailer.

About the programme:

ET MSMEs Awards was introduced to identify the top MSMEs in the country and highlight the good work the sector is doing. The first and second editions of ET Rise MSMEs Ranking saw a participation of over **8,000 and 10,000 businesses respectively**, out of which the top-ranked MSMEs were identified through a rigorous evaluation process. In both the previous editions the top-ranked businesses were felicitated in a digital event that witnessed the leading voices of the MSME ecosystem.

This year the **Final Felicitation Day** will be an on-ground event which will serve as an agenda-setting forum for industry leaders, policymakers, and the entrepreneurial ecosystem to define actionable strategies and solutions to boost the global competitiveness of MSMEs and strengthen the industry, shaping the new India growth story.

This year Economic Times Digital will award and recognize MSMEs in **26 different categories**.

1. Overall industry awards (6 Awards)

- a. Indian MSME of the Year Award (**1 for services; 1 for manufacturing**)
- b. Global Indian MSME of the Year Award (**1 for services; 1 for manufacturing**)
- c. India's Top Exporter of the Year Award (**1 for services; 1 for manufacturing**)

2. Awards by each MSME category (9 awards)

- a. India's Top-Performing MSME of the Year Award (1 for Micro, 1 for Small, 1 for Medium)
- b. India's Fastest-growing MSME Award (1 for Micro, 1 for Small, 1 for Medium)
- c. India's Top Innovative MSME of the Year Award (1 for Micro, 1 for Small, 1 for Medium)

3. MSME Enabler Awards (2 Awards)

- a. Indian MSME Enabler Award for Tech & Innovation
- b. Indian MSME Enabler Award for Banking & Financing

4. Special Award Categories (5 awards)

- a. Top-performing Listed SME (1 for Listed SMEs)
- b. Indian MSME Women Entrepreneur of the Year Award (1 for Micro; 1 for Small; 1 for Medium)
- c. Best CSR Initiative by an SME (1 for Medium)

5. Industry Focussed Award Categories (4 awards) - These are all manufacturing sector focused

- a. **Automobile & OEM MSME of the Year**
- b. **Pharmaceutical & Healthcare MSME of the Year**
- c. **Electrical & Electronics MSME of the Year**
- d. **Clothing & Apparel MSME of the Year**

Key KPI of the Event:

- 10000+ Registrations
- 15Mn+ Reach
- 10Mn+ Impressions
- 1Mn+ Video Views
- 300+ Minutes of content
- 30+ speakers
- 10+ sessions

Kindly, use the UTM tracker embedded URL for the registration purpose.

https://economictimes.indiatimes.com/engage/et_msmeawards2022.cms?utm_source=Ext7&utm_medium=PromoMailer1&utm_campaign=ETMSMEAwards

We sincerely request our MSMEs members to actively support and participate in this **Economic Times MSME Awards 2022**.

Thanks & regards,

Daara B Patel
Secretary – General



POWERED BY



PLATINUM PARTNER | GOLD PARTNERS | BANKING PARTNER



Partner Association 

Last date for Registration - 31st October 2022



INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA)

102, Poonam Chambers, A Wing, 1st Floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018. Maharashtra, India. Tel: +91-22-24974308 / 24944624 Email: actadm@idmaindia.com Website: www.idma-assn.org

REGISTER
NOW

INDIAN DRUG MANUFACTURERS' ASSOCIATION (IDMA)

REGISTER
NOW

Organizes

Symposium on Nasal and Pulmonary Drug Delivery

Hotel Sofitel, BKC, Mumbai,
November 10 & 11, 2022



Indian Drug Manufacturers' Association (IDMA) is proud to present the Two-Day "**Symposium on Nasal and Pulmonary Drug Delivery**" on Thursday, 10th & Friday, 11th November 2022 at Hotel Sofitel, BKC, Mumbai.

The Indian Pharmaceutical Industry is showing increasing interest in developing **orally inhaled and nasal products (OINDP)** compared to conventional dosage forms as they provide significant benefits to patients, including minimal systemic exposure, faster onset of action, and broader options for disease management. New therapeutic agents such as proteins, peptides and nucleic acid based agents are being developed every year, making it vital to find a non-invasive route such as nasal or pulmonary for their administration.

These developments represent significant opportunities for pharmaceutical companies, provided they choose delivery systems that adequately "partner" each drug during its development.

Nasal and pulmonary delivery are non-invasive routes of administration that target the delivered dose directly to the site of drug action. Drug delivery to the respiratory area can also be used for systemic delivery of peptides and proteins due to the large surface area for drug absorption.

Nasal and pulmonary drug delivery systems are used for local and systemic treatment of diseases such as asthma, chronic obstructive pulmonary disease (COPD), rhinitis, migraine and many more. New inhalation products are being developed for non-respiratory disease indications, e.g. diabetes, which would allow patients to avoid more intrusive medical treatments. Drug delivery device used in these products is far more than an instrument for the administration of the formulation.

The device is part of the primary packaging, is part of the container closure, and is the vehicle to transport successfully the active medicine to the target. During the dispensing act the responsibility of the effect of the therapy switches to the device. Delivery devices for nasal and pulmonary applications require additional particular attention during development and production as their performance characteristic and reliability has a crucial impact on the efficiency of the nasal or pulmonary delivery to the target site.

Request members to kindly register and attend this Symposium along with their concerned personnel.

The Registration fee for the same would be as follows: -

- **Delegate - Rs.12,000 + GST @ 18% per Delegate**
- **Student - Rs.6,000 + GST @ 18% per Student**

* *Early bird discounts - Before 21st October 2022: 10% discount*

* *Group registration benefits (for 3 or more): 15% discount*

RTGS Details:

Account Holder's Name: Indian Drug Manufacturers' Association

Current Account Number: 76080200000242

Bank: Bank of Baroda

IFSC Code: BARB0DBWORL

Branch: Worli, Mumbai 400 018

For any further clarifications / assistance, please feel free to call :

Ms. Sapna Patil - (9619802299 / admin@idmaindia.com) &

Mr. Melvin Rodrigues (9821868758 / actadm@idmaindia.com)

We would be forwarding more information on this symposium at the earliest.

Thanks & regards,

Daara B Patel

Secretary – General



REGISTRATION FORM

To,
The Secretary General
Indian Drug Manufacturers' Association
102/B, A Wing, Poonam Chambers, Worli, Mumbai 400 018.
Tel. # 022 - 24974308 / 24944624
E-mail: admin@idmaindia.com / actadm@idmaindia.com

Date:

Dear Sir,

Symposium on Nasal and Pulmonary Drug Delivery **Hotel Sofitel, BKC, Mumbai | November 10 & 11, 2022**

Kindly register the name/s of the following person/s from our company to participate in the above programme: -

SR. NO.	NAME	DESIGNATION	MOBILE NOS.	EMAIL
1				
2				
3				
4				
5				

Our Cheque/ DD / RTGS details : _____ dated _____ for

Rs. _____ is enclosed.

Thanking you,

Yours faithfully,
(Name & Designation)

Name of the Company _____

Address _____

Tel No. : _____ Fax No. : _____ E-Mail: _____

The Registration fee for the same would be as follows: -

- **Delegate** - **Rs.12,000 + GST @ 18% per Delegate**
- **Student** - **Rs.6,000 + GST @ 18% per Student**

* *Early bird discounts - Before 21st October 2022: 10% discount*

* *Group registration benefits (for 3 or more): 15% discount*

RTGS Details:

Account Holder's Name: **Indian Drug Manufacturers' Association**

Current Account Number: **76080200000242**

Bank: **Bank of Baroda**

IFSC Code: **BARB0DBWORL**

Branch: **Worli, Mumbai 400 018**

Amendment in Standard Input Output Norms (SION) of 'Chemical & Allied Product' (Product Code 'A') - reg.

Public Notice No. 30/2015-20, dated 12th October, 2022

- In exercise of the powers conferred under Paragraph 1.03 and 2.04 of the Foreign Trade Policy (FTP), 2015-20, as amended from time to time, the Director General of Foreign Trade hereby makes the amendments in the Standard Input Output Norms (SION).
- The Standard Input Output Norms (SIONs) appearing at the following serial numbers corresponding to the export item are suspended with immediate effect:

SION No.	Export Product
A254	Guanidine Nitrate
A257	Hexahydrothymol/ Menthol BP/USP
A282	Magnesium Glycerophosphate BPC 63
A1939	Terpeneol
A1973	Deltamethrin 2.8% W/W or 2.5% W/VEC (Density 0.89 gm/ML)
A2061	Blend of Aromatic Polyester Polyols, Amino Polyols

A2331	Cefuroxime Axetil Amorphous
A2539	Pure Glyceyl Mono Stearate with max Glycerine 0.5%
A2818	Lamivudine
A3056	Trans-4-Amino-Cyclo Hexanol
A3486	Cineole

- An exporter desirous of obtaining Advance Authorization for above mentioned export products may apply for it under Para 4.07 of Handbook of Procedures Vol. I (2015-20).

Effect of this Public Notice: Standard Input Output Norms (SION) appearing at **A254, A257, A282, A1939, A1973, A2061, A2331, A2539, A2818, A3056 and A3486** are suspended with immediate effect.

F. No. 01/82/171/00001/AM23/DES-III

Santosh Kumar Sarangi, Director General of Foreign Trade & Ex-officio Addl. Secy., Directorate General of Foreign Trade, Ministry of Commerce And Industry, Department of Commerce, New Delhi.



Have you renewed your Membership for the years

2021-2022 & 2022-2023

If not, please do so; kindly contact IDMA Secretariat at:
 Email: actadm@idmaindia.com / accounts@idmaindia.com
 Tel.: 022 - 2494 4624 / 2497 4308 / Fax: 022 - 2495 0723

Direct Tax Collections for F.Y. 2022-23 up to 08.10.2022

dated 09th October, 2022

The provisional figures of Direct Tax collections up to 8th October, 2022 continue to register steady growth.

Direct Tax collections up to 8th October, 2022 show that gross collections are at Rs. 8.98 lakh crore which is 23.8% higher than the gross collections for the corresponding period of last year. Direct Tax collection, net of refunds, stands at Rs.7.45 lakh crore which is 16.3% higher than the net collections for the corresponding period of last year. This collection is 52.46% of the total Budget Estimates of Direct Taxes for F. Y. 2022-23.

So far as the growth rate for Corporate Income Tax (CIT) and Personal Income Tax (PIT) in terms of gross

revenue collections is concerned, the growth rate for CIT is 16.73% while that for PIT (including STT) is 32.30%. After adjustment of refunds, the net growth in CIT collections is 16.29% and that in PIT collections is 17.35% (PIT only)/16.25% (PIT including STT).

Refunds amounting to Rs.1.53 lakh crore have been issued during the period 1st April, 2022 to 8th October 2022, which are 81.0% higher than refunds issued during the same period in the preceding year.

Surabhi Ahluwalia, Pr. Commissioner of Income Tax (OSD), Media & Technical Policy, Official Spokesperson, CBDT, Ministry of Finance, Department of Revenue, Central Board of Direct Taxes, New Delhi.



INDIAN DRUGS ONLINE

PUBLISHED ON 28th OF EVERY MONTH

ADVERTISEMENT BANNER RATES FOR INDIAN DRUGS WEBSITE

(Rates in Rupees per insertion)

Position	Size	RATE	VALIDITY
Right Side Banner	180 X 150 Pixel	25,000	3 MONTHS
Left Side Banner	180 X 150 Pixel	25,000	3 MONTHS

Terms and Conditions

- All payments by DD in advance only to be made in favour of **Indian Drug Manufacturers' Association**, payable at Mumbai
- 25% discount applicable only for IDMA members
- 15% discount is applicable on Annual Contract for Non IDMA Members
- Please provide Banner Artwork as per the size for advertisements before the deadline
- **Advertisement material must reach us 10 days before the date of release**

For more details please contact: **Publications Department**

Indian Drug Manufacturers' Association

102-B, Poonam Chambers, Dr A B Road Worli, Mumbai 400 018. Tel: 24944624/24974308 Fax: 24950723

Email: publications@idmaindia.com / actadm@idmaindia.com

Website: www.idma-assn.org / www.indiandrugsonline.org

DPIIT invites suggestions to enhance Ease of Doing Business and Ease of Living

Sahaj Karobar avam Sugam Jeevan Hetu Sujhav

About

Government of India is committed to improve Ease of Doing Business and Ease of Living across the country. Multitude of reforms have been implemented over the last few years to improve Government's interface with businesses and citizens. In the Amrit kaal of Independence, Government is marching ahead rapidly to create a transparent system, efficient process and smooth governance to make development all-round and all-inclusive.

Objective

DPIIT is inviting suggestions from businesses and citizens to enhance Ease of Doing Business and Ease of Living focusing on what kind of problems are faced in starting and running a business. Also, minor violations under which Provisions/Sections of the Acts/Rules are to be decriminalized. The aim is to make 'New India' a preferred investment destination across the globe and ensure hassle-free service delivery to the ultimate beneficiary.

Participating Guidelines

Participants have to share suggestions, related to issues faced by businesses or citizens, across categories. Information across fields is to be provided by selecting correct option from drop-down menu, wherever available. Suggestions are to be submitted in a clear and concise manner along with selection of correct Department of a Central Ministry or a State/ Union Territory. Participants need to fill separate forms for submitting different suggestions across different categories or Government Departments.

Problem Domains

Following are the broad areas for which suggestions may be submitted to improve *Ease of Doing Business and Ease of Living*:

- Getting Certificates, Licenses, Permissions, Approvals

- Renewal of Certificates, Licenses, Approvals
- Decriminalization of minor offences
- Filings>Returns
- Inspections/Audits
- Online systems/process
- Maintaining Registers & Records
- Applying for Incentives
- Payment of Incentives
- Procedural/Guidelines related
- Payment mechanism
- Others

Timelines

Start Date	29th September 2022
Last date	15th October 2022

Terms and Conditions

- All businessmen and aspiring entrepreneurs, who have invested in India or planning to invest in India, and Indian citizens may participate
- **Incomplete and incorrect** forms will not be considered
- All entries obtained through unauthorized sources or which are incomplete, illegible, mutilated, altered, reproduced, forged, irregular, or fraudulent in any way or otherwise not in compliance with the rules are automatically void
- Once a suggestion is submitted, DPIIT may correspond with the participant for supplementary information, if necessary
- Organizers reserve the right to cancel the campaign or modify the rules, dates of the campaign anytime. The Organizers shall have no liability whatsoever for any inconvenience/loss directly or indirectly caused to any Participant due to such modification of rules/cancellation of campaign and the participants

shall accordingly not be entitled to raise any claims pertaining to the same

- The organizers reserve the right to select or reject any submission without assigning any reasons whatsoever and without thereby incurring any liability to the participant(s) whatsoever.
- Once the participants have made submissions on the platform, they shall have no claim even

in the event of stoppage/cancellation of the competition.

- If any question, dispute or difference arises between the applicant and DPIIT, then the decision of Secretary, DPIIT is final and binding

Note: Members are requested to visit <https://innovateindia.mygov.in/suggestion-box/> for detail information



IDMA BULLETIN SUBSCRIPTION FORM

Date : _____

To

The Subscription Department
 Indian Drug Manufacturers' Association ,
 102-B, Poonam Chambers, Dr. A. B. Road, Worli, Mumbai – 400 018, India.
 Email: admin@idmaindia.com /accounts@idmaindia.com / Web: www.idma-assn.org
 Kindly enter my subscription to "IDMA Bulletin".

The details are as follows:

Name of the subscriber
 Current institutional attachment
 Designation
 Delivery Address
 City Pin code State
 Country Phone no. (with STD/ISD code) E-mail address

Subscription details

Subscription Period: One year
Subscription Type: India / Foreign
Subscription starts from: Month Year.....

Payment details

Cheque No Dated Drawn on Amount Date:

Signature of the subscriber

Annual subscription rates:

India (INR)

Members	Government Research/Educational Institutions	Non-Members
1000	2000	4000

Overseas (US\$) :-

Individual
USD 400

Kindly note: IDMA Bulletin is Published on 7th, 14th, 21st and 30th of every Month.
(IDMA GSTIN:27AAATI3594D1Z0)

- Subscriptions are for calendar year only
- Please return the filled form to the above mentioned address.
- Cheque should be issued in favour of "Indian Drug Manufacturers' Association", payable at Mumbai.
- Please allow at least two weeks for commencement of new subscription.
- Claims for missing issues can be made only within fifteen days of publication

Cruising Towards TB Elimination

On September 9, 2022, Indian President Droupadi Murmu had launched the Pradhan Mantri TB Mukht Bharat Abhiyaan to reinvigorate the mission of TB elimination from the country by the year 2025. Earlier, at the Delhi End TB Summit in March 2018, Prime Minister Narendra Modi had given a clarion call to the health authorities to end TB in the country five years ahead of global target of 2030. The Pradhan Mantri TB Mukht Bharat Abhiyaan has been envisioned to bring together all community stakeholders to support those on TB treatment and accelerate the country's progress towards TB elimination. The President also launched the Ni-kshay Mitra initiative which forms a vital component of the Abhiyaan.

The Ni-kshay Mitra portal provides a platform for donors to provide various forms of support to those undergoing TB treatment. The three-pronged support includes nutritional, additional diagnostic, and vocational support. The donors, called Ni-kshay Mitras, could be a wide range of stakeholders, including corporate houses and industry representatives. That the Indian government is determined to eradicate this deadly disease from the country is clear from the fact that the government has been taking several measures during the last some years, and even during the pandemic period the government did not lose its focus.

In the year 2018, faced with the alarming situation of emergence of multidrug-resistant TB as a public health crisis, the Union health ministry had made failure to report TB cases to the health authorities a criminal offence. The result is there for everybody to see as there has been a steady increase in the number of TB cases reported to the government which is very crucial as notification is an important tool to achieve universal coverage and succeed in the fight against this fatal disease.

Of course, during the last some years, the Central govt has introduced pivotal initiatives that are changing the way TB is diagnosed, treated and prevented in the country. To make India a TB-free nation by the year 2025, the Union Health Ministry has periodically been taking several laudable steps. The last few years have seen the country take definitive steps towards the elimination of tuberculosis from the country. The sustained efforts of

the National Tuberculosis Elimination Programme have led to an unprecedented increase in TB notifications and significant improvements in timely diagnosis, adherence, and treatment outcomes.

To eradicate this dreaded disease from the country, the Ministry in the year 2018 made the Revised National Tuberculosis Control Programme (RNTCP) more broad-based by mandating as many as 49,050 private clinics to prescribe free drugs to the TB patients.

The government is implementing this scheme with the support of field level staff and an inventory management system called 'Nikshay Aushadhi' has been deployed for the purpose. And, in October 2019, the Health ministry had launched a country-wide 'TB Harega Desh Jeetega' campaign for community participation in the fight against TB.

As part of the end-TB campaign, the government had also established patient forums in over 95 per cent of all districts in the country and these district forums would bring the voices of the affected to the fore, and highlight on-ground challenges faced by patients and their families in accessing TB care services.

The Indian government's initiative is laudable as India has the world's highest TB burden, with 2.6 million cases and around 450,000 fatalities annually which is more than 1 quarter of the global disease burden. India accounts for a quarter of the world's DR-TB and fewer than 50% of patients put on treatment are having successful treatment outcomes. The government seems to be well on path to eliminate TB by 2025.

Source: Ramesh Shankar, Pharmabiz, 05.10.2022



IPC launches 1000th IP Reference Standard

With the launch of Sitagliptin Impurity A, the inventory of Indian Pharmacopoeial Reference Standards has reached the 1000 mark. The Indian Pharmacopoeia Commission (IPC) has become the third Pharmacopoeia Commission in the world to have more than 1000 Pharmacopoeial Reference Standards in its inventory.

Sitagliptin is a dipeptidyl peptidase-4 inhibitor and used to improve glycemic control in patients with type 2 diabetes.

During the 50th Scientific Body meeting of Indian Pharmacopoeia Commission on September 28, 2022, 1000th IP Reference Standard- Sitagliptin Impurity A was launched by members of the Scientific Body.

Sitagliptin is among 15 impurities launched by IPC recently. The other impurities are Amiodarone Impurity A, Amiodarone Impurity B, Amlodipine Impurity D, Cefradine, Cephadrine, Diazepam Impurity B, Econazole Nitrate, Fenbendazole Impurity B, Fluconazole Impurity C, Indapamide Impurity A, Norfloxacin Impurity E, Quetiapine Impurity A, Teneligliptin Impurity C, 6-chloro-3-hydroxyamide (Chlor Homolog impurity).

IPC launched the first Reference Standard of anti-diabetic drug, Pioglitazone in 2010. Later Indian Pharmacopoeia 2014 contained separate monographs for anti-diabetic drugs, metformin tablets and metformin prolonged release tablets.

In August this year IPC added five new Indian Pharmacopoeial Reference Standards and seven new impurity reference substances to Indian Pharmacopoeia 2022. The list of impurity reference substances contained clobazam impurity A, levocetirizine amide, lumefantrine related compound A, quetiapine impurity I, tamoxifen citrate impurity standard, tinidazole impurity B, trimethoprim impurity B.

On the other hand, the list of Indian Pharmacopoeial Reference Standards included disopyramide phosphate, dolutegravir sodium, estradiol hemihydrate, propofol, tenofovir alafenamide fumarate.

Impurity standards are used to perform the system suitability, qualitative and quantitative parameters for compliance to Indian Pharmacopoeia monograph.

The IP is a legally recognized book of standards for drugs and their formulations in India. The standards of identity, purity and strength prescribed in IP are to ensure quality of the medicine. The mandate of the commission is to perform, inter-alia, functions such as revision and publication of the Indian Pharmacopoeia and National Formulary of India on a regular basis besides providing IP reference substances and training to the stakeholders on pharmacopoeial issues. Buying Indian Pharmacopoeial

Reference Standard is a social and legal responsibility of the industry, stated the commission.

Source: Laxmi Yadav, Pharmabiz, 03.10.2022

Codeine cough syrup rules may get tighter



AHMEDABAD: The central government could introduce new guidelines to monitor the supply and distribution of codeine-based cough syrups (CBCSs). The government was considering banning CBCSs, but the pharma industry asked for stricter guidelines to monitor their supply instead. As of now, manufacturers have a quota manufacture of codeine cough syrups, but the government could introduce rules for distributors and retailers to ensure these syrups do not reach unofficial outlets such as paan shops.

An office-bearer of the Indian Drug Manufacturers' Association (IDMA), on condition of anonymity, said, "We have requested the central government to not ban codeine-based cough syrups but to make its supply stricter. Codeine is used by medical professionals to treat cough, and manufacturers get a quota from the government.

There have been instances of codeine cough syrups seized at paan shops or from unauthorized sellers, but medically-proven cough syrups should not be banned because of this. According to official data, in the last three years, total consumption of codeine phosphate was 1.50 lakh kg and seizures of CBCS was only 21.5kg, meaning only 0.014% of the amount consumed was seized. Codeine was categorized as an essential narcotic drug in 2015 under the rules of the Narcotic Drugs and Psychotropic Substances (NDPS) Act."

He said a high-level meeting was held recently with top officials and several solutions were discussed. "As of now, it appears that codeine-based cough syrups will not be banned but their supply will be closely monitored. New guidelines may be introduced to control misuse of codeine cough syrups. If an unauthorized person is caught selling it, the authorities will hold the distributor who sold the syrup to that person responsible. Also, doctors may be told to write prescriptions with clear instructions about codeine," the IDMA official said.

Jashvant Patel, president of Federation of Gujarat State Chemists and Druggists Association said, "Most retail chemists obey the rules because this comes under the NDPS Act but there are some leaks in supply chains and it reaches unauthorized persons. Codeine monitoring should be more stringent to ensure it is not misused."

Source: *The Times of India*, 10.10.2022



Govt planning 7-8 more PLI schemes to expand coverage

The schemes will be launched at a time when India's economic growth faces strong external headwinds, mainly the Ukraine war and global growth slowdown. Several agencies have now scaled down their FY23 forecasts for the country.



The move follows 'good response' to the 14 such schemes, which have been announced since 2020 and are estimated to lead to an incremental manufacturing of more than \$500 billion over five years. (File)

The government is planning to launch 7-8 production-linked incentive (PLI) schemes in the next round soon in a bid to further expand the coverage across critical

manufacturing sectors, stimulate economic growth and spur job creation, official sources said.

The new PLI schemes will cover segments, including textiles, electronic components, furniture, toys and leather, said the sources. Tens of thousands of crores would be extended as incentives. The government intends to make fresh budgetary allocation for the schemes, apart from using savings from the earlier PLI schemes.

The move follows 'good response' to the 14 such schemes, which have been announced since 2020 and are estimated to lead to an incremental manufacturing of more than \$500 billion over five years. The new schemes will be rolled out, as part of broader government effort to push for growth without exacerbating inflationary pressure, said one of the sources.

The government had approved three PLI schemes for mobile & specified electronic components, pharmaceuticals API (Active Pharmaceutical Ingredients) and medical devices in the first round in March 2020. The total initial outlay for these three programmes was to the tune of ₹51,311 crore over five years.

In the second round, another 11 schemes were cleared by the Cabinet in November 2020, with a total initial allocation of ₹1.46 trillion over a five-year period. The sectors covered were electronic/technology products, pharmaceuticals, telecom & networking products, food products, white goods, solar modules, automobiles & auto components, advance chemistry cell battery, textiles, specialty steel and drones.

However, the sector-wise allocation was later tweaked, based on re-assessed priorities, which generated some savings. For instance, the outlay for the auto sector was reduced to ₹25,938 crore from ₹57,042 crore. For technical and man-made fibre-based textiles, the revised outlay stood at ₹6,013 crore, against ₹10,683 crore earlier; it created scope for another PLI scheme for this labour-intensive sector.

"The government continues to believe the PLI schemes will be a 'game changer' because it has potential to boost manufacturing, economic growth and job prospects. On top of that, since the schemes are not demand-side stimulus measures, chances of them stoking price pressure, when inflation is already elevated, are muted," said a source.

PLI schemes are crucial to the country's ambition to expand the share of manufacturing in the country's GDP to 25%; the share has remained stagnant at 16-17% over the past three decades. Elevated manufacturing will ultimately spur exports as well and create a few global champions in each of the sectors.

The schemes will be launched at a time when India's economic growth faces strong external headwinds, mainly the Ukraine war and global growth slowdown. Several agencies have now scaled down their FY23 forecasts for the country.

Most recently, the World Bank slashed its growth forecast for India to just 6.5% for FY23 from 7.5% earlier, as it presented the gloomiest projection among independent agencies. Some analysts are projecting a further deceleration in growth in FY24-Nomura pegs it at just 5.7%. Against this backdrop, the PLI schemes may turn out to be a key growth lever.

Source: Financial Express, 11.10.2022



Pharma Exporters clock big gains

Gujarat-based pharma manufacturers are happy as dollar gains are not just translating into higher realisations, but an added competitiveness is expected to translate into more order volumes.

Indian Drug Manufacturers' Association (IDMA) president, Viranchi Shah, said, "Pharma exports stood at \$24billion in the last fiscal year which is already growing at 6%. We hope for better exports this year. Exports margins will increase due to a strong dollar. While the imports of active pharmaceutical ingredients (API) will certainly get costlier; formulations will provide more benefits to domestic manufacturers.

Drug makers hope for better margins and competitiveness. "Gujarat is the pharmacy capital of India, and the state is the leading pharma exporter with around 30% contribution. A stronger dollar against the Indian rupee will help companies get better margins and increase exports with more competitiveness. The demand has been increasing steadily since Covid and we are working on more domestic

API production to reduce import dependence." Said Atul Shah, Secretary, Small Scale Indian Drug Manufacturers' Association (SSIDMA).

Source: The Times of India, 10.10.2022



Biocon Foundation Receives 'Mahatma Award 2022 for Excellence in Social Good'

Biocon Foundation, the CSR (corporate social responsibility) arm of the Bengaluru-headquartered Biocon Limited, has been conferred with the '**Mahatma Award 2022 For Excellence in Social Good**'. The awards were presented on the eve of the Birth Anniversary of the Father of the Nation **Mahatma Gandhi in New Delhi**.

Mahatma Awards were founded and instituted by social entrepreneur and philanthropist Amit Sachdeva, better known as 'The CSR Man of India' and are supported by Aditya Birla Group.

Biocon Foundation has received the award under the 'Sustainable Cities and Communities' category for the work done by the Foundation in Bengaluru city. This award recognizes the organizations working towards making cities and human settlements inclusive, safe, resilient, and sustainable.

Dr Anupama Shetty, Mission Director, Biocon Foundation, received the award at a function held in New Delhi at the India International Centre. The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities.

Some of these were contributing to the urban mobility solution i.e. BMRCL's Hebbagodi Metro Station, Hebbagodi Lake Rejuvenation, transformation of the Minsk Square traffic island, creating urban micro-forests in Dakshina Kannada. It also aims to provide access to safe and inclusive public spaces, particularly for the women and children.

Source: Free Press Journal & www.biocon.com, 07.10.2022





60TH IDMA ANNUAL PUBLICATION 2022 IN THIS ISSUE

- Success Stories
- Export of Bulk Drugs and Intermediates (All Countries) during the year 2020-21 and from April 2021 to December 2021.
- Import of Bulk Drugs and Intermediates (All Countries) during the year 2020-21 and from April 2021 to December 2021
- Export of Drug Formulations and Biologicals (All Countries) during the year 2020-21 and from April 2021 to December 2021
- Import of Drug Formulations and Biologicals (All Countries) during the year 2020-21 and from April 2021 to December 2021
- New Drugs Approved for Marketing by Drugs Controller General (I) during the Period January 1961 to 31st December 2021
- Approved BA/BE Centres In India
- Health Statistics of India

*SPECIAL
RATE FOR
IDMA MEMBERS
ONLY ₹ 1000/-
(₹200/- extra
towards Courier
Charges)

Payment can be made either by Cheque/Demand Draft in favour of **Indian Drug Manufacturers' Association**, payable at Mumbai OR through NEFT/RTGS to the following Account: Account Name : **Indian Drug Manufacturers' Association**, Bank A/c No.: Current A/c **7608020000242**
Bank : **BANK OF BARODA**, Branch Address : Worli Branch, Mumbai-18,
IFSC Code: **BARB0DBWORLD** MICR CODE : **400012232**



Contact: **Publications Department**

INDIAN DRUG MANUFACTURERS' ASSOCIATION

102, A Wing, Poonam Chambers, Dr. A. B. Road, Worli, Mumbai - 400018, Maharashtra, India.

Tel No. 022 24974308 / 24944624 Fax No. 022 24950723

Email: admin@idmaindia.com / actadm@idmaindia.com

Web: www.idma-ass.org / www.indiandrugonline.org



IDMA PUBLICATIONS RATE CARD

Sr. No.	Name of Publications	Cost in ₹
1.	IDMA BULLETIN (Annual Subscription – 48 Issues) (<i>Published on 7th, 14th, 21st and 30th of every month</i>)	
	• Members	1000/- p.a.
	• Government Research / Educational Institutions	2000/- p.a.
	• Non-Members	4000/- p.a.
2.	INDIAN DRUGS (Annual Subscription – 12 Issues) (<i>Published on 28th of every month</i>)	
	• Members	1000/- p.a.
	• Students	1000/- p.a.
	• Government Research / Educational Institutions	2000/- p.a.
	• Non-Members	4000/- p.a.
3.	IDMA APA Forum	
	• Annual Membership	500/-
	• Life Membership	5000/-
4.	TECHNICAL MONOGRAPHS	
	NO. 1: STABILITY TESTING OF EXISTING DRUG SUBSTANCES AND PRODUCTS	400/-
	NO. 2: PRIMARY & SECONDARY CHEMICAL REFERENCE SUBSTANCES	400/-
	NO. 3: INVESTIGATION OF OUT OF SPECIFICATION (OOS) TEST RESULTS	400/-
	NO. 4: PHARMACEUTICAL PREFORMULATION ANALYTICAL STUDIES	400/-
	NO. 5: ENVIRONMENTAL MONITORING IN CLEANROOMS	400/-
	NO. 6: CORRECTIVE/PREVENTIVE ACTIONS (CAPA) GUIDELINE	400/-
	NO. 7: DATA INTEGRITY GOVERNANCE	400/-
5.	TECHNICAL DOCUMENT QUALITY 4.0 DIGITAL TECHNOLOGY OF THE FUTURE	500/-
6.	IDMA MEMBERSHIP DIRECTORY	1,500/-
7.	IDMA ANNUAL PUBLICATION	1,500/-

KINDLY NOTE:

- Mailing of IDMA Bulletin and Indian Drugs by Post will commence prospectively only after receipt of payment.
- All payments may be made in advance by Cheque / DD / RTGS / NEFT only in favour of: **“Indian Drug Manufacturers’ Association”**.

For RTGS/NEFT: Name: BANK OF BARODA, **Branch:** Worli, **Name of Account Holder:** INDIAN DRUG MANUFACTURERS’ ASSOCIATION, **Account No.** Current A/c 76080200000242, **IFSC :** BARB0DBWORLD, **MICR CODE :** 400012232

- Courier charges for Publications under Serial Nos. 4 to 7 will be extra as applicable.
- Please intimate us details through email immediately after making the remittance through RTGS/NEFT, so as to enable us to do the needful promptly.
- GST will be charged extra, as applicable.

INDIAN DRUG MANUFACTURERS’ ASSOCIATION

102-B, “A”-Wing, Poonam Chambers, Dr A B Road, Worli, Mumbai 400 018. Tel: 2494 4624 / 2497 4308 Fax: 022- 2495 0723
Email: admin@idmaindia.com/publications@idmaindia.com, Website: www.idma-assn.org / www.indiandrugsonline.org



NOW AVAILABLE ! IDMA-APA GUIDELINES / TECHNICAL MONOGRAPHS

TECHNICAL MONOGRAPH NO. 1
**STABILITY TESTING OF EXISTING
DRUGS SUBSTANCES AND PRODUCTS**

TECHNICAL MONOGRAPH NO. 3
**INVESTIGATION OF OUT OF SPECIFICATION
(OOS) TEST RESULTS**

TECHNICAL MONOGRAPH NO. 5
**ENVIRONMENTAL MONITORING
IN CLEANROOMS**

TECHNICAL MONOGRAPH NO. 7
DATA INTEGRITY GOVERNANCE

TECHNICAL MONOGRAPH NO. 2
**PRIMARY & SECONDARY CHEMICAL
REFERENCE SUBSTANCES**

TECHNICAL MONOGRAPH NO. 4
**PHARMACEUTICAL PREFORMULATION
ANALYTICAL STUDIES**

TECHNICAL MONOGRAPH NO. 6
**CORRECTIVE/PREVENTIVE ACTIONS
(CAPA) GUIDELINE**

TECHNICAL DOCUMENT NO. 8
**QUALITY 4.0 DIGITAL
TECHNOLOGY OF THE FUTURE**

Copies are available at IDMA Office, Mumbai. We do not mail any publications against VPP payment.
All payments to be made in advance as Cheque/DD/RTGS/NEFT in favour of "**INDIAN DRUG
MANUFACTURERS' ASSOCIATION**" at Mumbai.

For more details please contact: **PUBLICATIONS DEPARTMENT** Tel.: 022 - 2494 4624 / 2497 4308 Fax: 022 - 2495 0723
E-mail: publications@idmaindia.com/actadm@idmaindia.com,
Website: www.idma-assn.org/www.indiandrugsonline.org



**For Advertising in the Classified Columns and also for series advertisements
please contact: Geeta Suvarna (+9820161419) Publications Department**

IDMA BULLETIN

Tel.: 022 - 2494 4624 / 2497 4308 / Fax: 022 - 2495 0723/
E-mail: publications@idmaindia.com,
Website: www.idma-assn.org, www.indiandrugsonline.org



IDMA BULLETIN

PUBLISHED ON 7th, 14th, 21st and 30th of Every Month

ADVERTISEMENT TARIFF

(Effective from 01.11.2017)

Magazine Size: 21.5 cm x 27.5 cm / Print Area: 18.5 cm x 23.5 cm

Position		Rate per Insertion ₹	
		B/W	Colour
Full Page (18 cm wd x 23.5 cm ht)	:	9,000	12,500
Half Page (18 cm wd x 11.5 cm ht) (Horizontal)		5,000	8,500
Half Page (8.5 cm x 23.5 cm) (Vertical)	:	5,000	8,500
Quarter Page (8.5 cm wd x 11.5 cm ht)	:	2,500	6,000
Strips Advts (4 cm ht x 18 cm wd)	:	2,500	-
Inside Cover Pages	:	-	18,000
Back Cover	:		25,000
Centre Spread (double spread) Print area (40cm wd x 27cm ht)	:	25,000	30,000

Terms and Conditions:

- All payments by **Cheque/ Demand Draft/RTGS** in advance only to be made in favour of “**Indian Drug Manufacturers’ Association**”, Payable at Mumbai

The RTGS details are as follows:- BANK: BANK OF BARODA

Account Name : **Indian Drug Manufacturers’ Association**, Bank A/c No. : Current A/c **7608020000242**

Bank : **BANK OF BARODA**, Branch Address : Worli Branch, Mumbai-18, **IFSC : BARB0DBWOL**

MICR CODE : 400012232

- GST will be charged extra, as applicable. (Current Rate is @5%)
- SPECIAL DISCOUNTS for Series Advertisements
- For colour advertisements, positives to be supplied otherwise processing charges to be paid.
- Advertisement material must reach us 7 days before the date of publication.**
- Positioning of the Advt other than Cover Positions will be at our discretion.
- Only Colour Advts will be entertained on Cover Positions.

Classified Advertisements

- Upto 80 words — ₹2,000/-
- 50% extra for Advt Box Number
- 50% extra for indent/layout spacing, bold captions, etc.
- ₹50/- extra for voucher copy
- Series discount not applicable for classifieds

For further details such as series discounts etc, please contact:

Melvin Rodrigues — Cell: +9821868758 (Email: actadm@idmaindia.com)/

Geeta Suvarna — Cell: +9820161419 (Email: publications@idmaindia.com)

PUBLICATIONS DIVISION

INDIAN DRUG MANUFACTURERS’ ASSOCIATION

102-B, Poonam Chambers, Dr. A. B. Road, Worli, Mumbai 400 018. Tel: 022-2494 4624/2497 4308 Fax: 022-2495 0723

Website: www.idma-assn.org/www.indiandrugsonline.org

INFINITE APPLICATIONS. **ONE IDENTITY.**

Dear Partner,

For over three decades, we have been dedicating ourselves to the pharmaceutical excipients industry in India. Three decades of relentless effort that has become our identity.

Today, that effort is evident in hundreds of applications across the arena of pharma, nutra and biopharma. And we are renewing our pledge to further enforce our efforts by focusing on one area - excipients. So we can continue to serve the industry and our partners even better, with greater efficiency and deeper integration.

Because while what we do leads to infinite ends, our identity remains uniquely unchanged - excipients.

Signet-ure

Identity

Signet

The Complete Excipients Company





The world needs you to succeed.



Let us help you get there faster, and safely.

Only a few ever reach the summit – those who possess the right combination of intelligence, resilience, bravery and respect – backed up by a team of experienced and expert partners.

As the challenge to deliver COVID-19 related vaccines and treatments continues, you can count on Aptar Pharma to help you achieve your goal.

As a global market leader, we can offer significant capacity for a wide range of proven injectable closure components designed to meet the specific needs of your COVID-19 developments.

Our proven multi-dose vial stoppers can reliably accommodate up to 20 piercings, enabling HCPs to vaccinate and treat more people more efficiently.

Aptar Pharma. Enabling the rapid deployment of your vaccine worldwide.

To reach the summit faster, and with less risk, contact **Estelle Verger**, Business Development Senior Manager, Aptar Pharma, at estelle.verger@aptar.com.



Delivering solutions, shaping the future.

Aptar 
pharma